Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B

NCT00922207 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00922207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00922207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
May 7, 2010
Completion date
September 29, 2014
Enrollment
280 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic